**Table S1**: Missing outcome data on prostate cancer (PCa) risk profiles among Black and non-Hispanic White (NHW) men diagnosed with first primary invasive PCa from 2004 to 2017 in California, using 4 risk categorizations as separate outcomes (prostate specific antigen [PSA], Gleason score [GS], stageand risk\*), by age

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Risk categories and age at diagnosis |   | NHW men |  | Black men |  | Black men and NHW men  |
|   | Outcome missing (%) |   | Total |  | Outcome missing(%) |  | Total |  | Outcome missing (%) |  | Total |
| ***PSA outcome models*** |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Age at diagnosis (y) |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  <55 |   | 7.0 |   |  |   | 12,555 |   | 6.2 |   |  |   | 3,818 |   | 6.8 |   |  |   |  16,373  |   |
|  55-64 |   | 7.5 |   |  |   | 48,011  |   | 6.8 |   |  |   | 9,288  |   | 7.4 |   |  |   |  57,299  |   |
|  65-74 |   | 9.5 |   |  |   | 57,038  |   | 8.3 |   |  |   | 7,681  |   | 9.3 |   |  |   |  64,719  |   |
|  75+ |   | 18.0 |   |  |   | 29,285  |   | 14.9 |   |  |   | 2,768  |   | 17.7 |   |  |   |  32,053  |   |
| ***GS outcome models***Age at diagnosis (y) |   |   |   |  |   |   |   |   |   |  |   |   |   |   |   |  |   |   |   |
|  <55 |   | 4.4 |   |  |   | 12,555  |   | 4.1 |   |  |   | 3,818  |   | 4.3 |   |  |   | 16,373  |   |
|  55-64 |   | 4.3 |   |  |   | 48,011  |   | 4.8 |   |  |   |  9,288  |   | 4.4 |   |  |   | 57,299  |   |
|  65-74 |   | 5.1 |   |  |   | 57,038  |   | 5.1 |   |  |   |  7,681  |   | 5.1 |   |  |   | 64,719  |   |
|  75+ |   | 10.2 |   |  |   | 29,285  |   | 10.8 |   |  |   |  2,768  |   | 10.2 |   |  |   | 32,053  |   |
| ***Stage outcome models***Age at diagnosis (y) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  <55 |   | 1.6 |   |  |   |  12,555  |   | 1.3 |   |  |   |  3,818  |   | 1.5 |   |  |   |  16,373  |  |
|  55-64 |   | 1.9 |   |  |   |  48,011  |   | 2.4 |   |  |   |  9,288  |   | 2.0 |   |  |   |  57,299  |  |
|  65-74 |   | 2.7 |   |  |   |  57,038  |   | 3.1 |   |  |   |  7,681  |   | 2.7 |   |  |   |  64,719  |  |
|  75+ |   | 6.0 |   |  |   |  29,285  |   | 6.8 |   |  |   |  2,768  |   | 6.1 |   |  |   |  32,053  |  |
| ***Risk outcome models***Age at diagnosis (y) |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |
|  <55 |   | 7.7 |   |  |   |  12,555  |   | 6.9 |   |  |   |  3,818  |   | 7.5 |   |  |   |  16,373  |  |
|  55-64 |   | 8.0 |   |  |   |  48,011  |   | 7.0 |   |  |   |  9,288  |   | 7.9 |   |  |   |  57,299  |  |
|  65-74 |   | 9.7 |   |  |   |  57,038  |   | 8.3 |   |  |   |  7,681  |   | 9.5 |   |  |   |  64,719  |  |
|  75+ |   | 15.3 |   |  |   |  29,285  |   | 12.6 |   |  |   |  2,768  |   | 15.0 |   |  |   |  32,053  |  |
| \* PCa risk stratification criteria based on the NCCN classification using TNM stage, GS and PSA level.  |
|  |